Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone for acute treatment of bipolar I mania or mixed episodes
2024-513037-20-00Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Lumateperone with Placebo (2 arms). Primary endpoint: Change from baseline to end of Week 3 in YMRS total score. Started Nov 2024; status: completed.
02
Drugs
lumateperone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2024-513037-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513037-20-00.